Skip to main content

33 Result(s)

within Kim Margolin Remove this filter Medicine & Public Health Remove this filter

Page of 2 next disabled
and

  1. No Access

    Article

    Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

    Dexrazoxane administration prior to short infusion doxorubicin prevents anthracycline-related heart damage. Since delivery of doxorubicin by 96-h continuous intravenous infusion also reduces cardiac injury, we...

    Warren A. Chow, Timothy W. Synold, Merry L. Tetef… in Cancer Chemotherapy and Pharmacology (2004)

  2. No Access

    Article

    Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

    Azidothymidine (AZT, zidovudine) has been shown to reverse cisplatin resistance in cell culture. This phase I study was performed to determine the maximally tolerated dose (MTD) and dose-limiting toxicities of...

    Robert J. Morgan Jr, Edward M. Newman… in Cancer Chemotherapy and Pharmacology (2003)

  3. No Access

    Article

    Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

    Preclinical studies in our laboratory have demonstrated that prior exposure to hydroxyurea increases the percentage of cells in S phase, enhancing the cytotoxicity of subsequent gemcitabine treatment in human...

    Yun Yen, Warren Chow, Lucille Leong, Kim Margolin… in Cancer Chemotherapy and Pharmacology (2002)

  4. No Access

    Article

    Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium

    Dolastatin-10 is a novel pentapeptide agentoriginally isolated from the marine molluskDolabella auricularia with amechanism of antitumor activity thatinvolves the inhibition of microtubuleassembly. We performed a...

    Kim Margolin, Jeffrey Longmate, Timothy W. Synold… in Investigational New Drugs (2001)

  5. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Janice Dutcher M.D., Michael B. Atkins, Kim Margolin, Geoff Weiss… in Medical Oncology (2001)

  6. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Michael B. Atkins, Janice Dutcher M.D., Geoff Weiss, Kim Margolin… in Medical Oncology (2001)

  7. No Access

    Article

    Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy

    Purpose: The purpose of these sequential phase I studies was to evaluate the antiemetic efficacy and pharmacokinetics of high-dose continuous infusion prochlorperazine. Methods: A total of 52 pat...

    Robert J. Morgan Jr, Timothy Synold, Brian I. Carr… in Cancer Chemotherapy and Pharmacology (2001)

  8. No Access

    Article

    Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

    A phase II trial of menadione [2.5 gm/m2 as a continuous intravenous (iv) infusion over 48 hours] followed by mitomycin C (10–20 mg/m2 iv bolus) administered every 4 to 6 weeks was performed in 23 patients with a...

    Merry Tetef, Kim Margolin, Chul Ahn, Steven Akman, Warren Chow… in Investigational New Drugs (1995)

  9. No Access

    Article

    Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial

    A phase II trial of menadione (2.5 g/m2 as a continuous intravenous infusion over 48 h) followed by mitomycin C (10–20 mg/m2 i.v. bolus) administered every 4–6 weeks was performed in 43 patients with advanced gas...

    Merry Tetef, Kim Margolin, Chul Ahn… in Journal of Cancer Research and Clinical On… (1995)

  10. No Access

    Chapter

    Fluorouracil and Leucovorin in Advanced Breast Cancer

    It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15–20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the co...

    James H. Doroshow, Kim Margolin… in Novel Approaches to Selective Treatments o… (1993)

  11. No Access

    Article

    Phase II study of 4 ′ -deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach

    4 ′-deoxydoxorubicin (DxDx) was administered to 17 patients with locally advanced or metastatic gastric adenocarcinoma. Treatment cycles were repeated every 21 days. 15 eligible patients with a Karnofsky perfo...

    George Somlo, James Doroshow, Steven Akman, Lucille Leong… in Investigational New Drugs (1991)

  12. No Access

    Article

    3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity

    3-Deazaguanine (Dezaguanine), a purine antimetabolite, was evaluated in a phase I trial in 42 patients with advanced solid tumors. Dezaguanine was given as a weekly intravenous infusion for three consecutive w...

    Kim Margolin, James Doroshow, Lucille Leong, Steven Akman… in Investigational New Drugs (1990)

  13. No Access

    Chapter

    Effective Salvage Therapy for Refractory Disseminated Breast Cancer with 5-Fluorouracil and High-Dose Continuous Infusion Folinic Acid

    Treatment options are limited for patients with disseminated carcinoma of the breast whose disease has progressed after therapy with standard chemotherapeutic programs (1). In fact, the usefulness of testing i...

    James H. Doroshow, Lucille Leong… in The Expanding Role of Folates and Fluoropy… (1988)

Page of 2 next disabled